Clinical trial Recruiting at 1 site Interventional Ages 18 to 60

Understanding how gut bacteria affect Type 2 Diabetes risk

Official title: Dissecting Host-microbiome Modifiers of Type 2 Diabetes Risk

Run by Laval University · NCT04579900 · Data updated 2026-11-12

This study is trying to see how changes in gut bacteria might affect blood sugar control in people with Type 2 Diabetes compared to those without it.

Quick facts

Study typeInterventional
Ages18 Years to 60 Years
SexAll
Enrollment40 (estimated)
SponsorLaval University
Academic / other
Locations1 site (Québec, Quebec)
StatusRecruiting
StartedFebruary 1, 2021
Main results expectedDecember 1, 2025
Study endsDecember 1, 2025
Registry record updatedMarch 18, 2025
Trial IDNCT04579900 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study include individuals diagnosed with Type 2 Diabetes or those who are not diagnosed but are at risk.

Probably not a fit

Patients currently taking oral hypoglycemic agents, lipid-lowering, or antihypertensive drugs may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the relationship between gut microbiota and Type 2 Diabetes (T2D) by examining how changes in gut bacteria may influence glucose control and insulin sensitivity. It aims to identify specific bacterial strains that contribute to dysbiosis and potentially disrupt the gut barrier in individuals with T2D. Through endoscopy and duodenal biopsy, researchers will collect samples from both T2D patients and non-T2D individuals to compare microbial signatures and understand their role in metabolic dysfunction.

Why it matters

Potential benefit: If successful, this research could lead to new strategies for preventing or managing Type 2 Diabetes by targeting gut microbiota.

How similar studies have gone: Other studies have shown promising results in understanding the role of gut microbiota in metabolic diseases, suggesting that this approach could yield valuable insights.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* T2DB de novo or non T2DB patients

Exclusion Criteria:

* oral hypoglycemic agents or lipidlowering or antihypertensive drugs

Where it's running

  • INAF, Université Laval
    Québec, Quebec, Canada
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.